J Gynecol Oncol.
2023 Jan;34(1):e3. 10.3802/jgo.2023.34.e3.
Contrasting clinical characteristics and treatment patterns in women with newly diagnosed advanced-stage epithelial ovarian cancer in Australia, South Korea and Taiwan
- Chou HH
1,2 - Fereday S3,4
- DeFazio A5,6,7
- Chang CL8
- Bowtell D3,4
- Hsu HC9
- Traficante N3,4
- Jeong SY10
- Cheng WF11
- Ariyarantne D3
- Australian Ovarian Cancer Study Group3
- Tung T12
- Rajadhyaksha V13
- Lee WH14
- Brown D15
- Kim BG16
- Affiliations
-
- 1Department of Obstetrics and Gynecology, Chang Gung Memorial Hospital at Linkou, Taoyuan, Taiwan
- 2School of Medicine, National Tsing Hua University, Hsinchu, Taiwan
- 3Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- 4Sir Peter MacCallum Cancer Centre, Department of Oncology, The University of Melbourne, Parkville, Vic, Australia
- 5Centre for Cancer Research, The Westmead Institute for Medical Research, Sydney, NSW, Australia
- 6The Daffodil Centre, The University of Sydney, a joint venture with Cancer Council NSW, Sydney, NSW, Australia
- 7Department of Gynaecological Oncology, Westmead Hospital, Sydney, NSW, Australia
- 8Department of Obstetrics and Gynecology, MacKay Memorial Hospital & Department of Medicine, MacKay Medical College, Taipei, Taiwan
- 9Department of Obstetrics and Gynecology, National Taiwan University Hospital Hsin-Chu Branch, Hsin- Chu City, Taiwan
- 10Department of Obstetrics and Gynecology, Kangnam Sacred Heart Hospital, The Hallym University School of Medicine, Seoul, Korea
- 11Department of Obstetrics and Gynecology, National Taiwan University Hospital, Taipei, Taiwan
- 12Medical Affairs, AstraZeneca International, Baar, Switzerland
- 13Medical Affairs, AstraZeneca United Kingdom, Cambridge, United Kingdom
- 14Medical Affairs, AstraZeneca South Korea, Seoul, Korea
- 15Medical Affairs, AstraZeneca Australia, Macquarie Park, NSW, Australia
- 16Department of Obstetrics and Gynecology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- KMID: 2552484
- DOI: http://doi.org/10.3802/jgo.2023.34.e3
Abstract
Objective
The real-world INFORM study analyzed sociodemographics, treatment patterns and clinical outcomes for patients with newly diagnosed advanced epithelial ovarian cancer (EOC) in Australia, South Korea (S.Korea) and Taiwan preceding incorporation of poly(ADP-ribose) polymerase inhibitors into clinical practice.
Methods
Retrospective data from patients diagnosed with EOC (high-grade serous EOC for Taiwan) between January 2014 and December 2018 with ≥12 months follow-up from diagnosis were analyzed descriptively. Survival was evaluated by Kaplan-Meier with two-sided 95% confidence interval (CI).
Results
Of the 987 patients (Australia, 223; S.Korea, 513; Taiwan, 251), 98% received platinum-based chemotherapy (CT). In S.Korea and Taiwan 76.0% and 78.9% respectively underwent primary cytoreductive surgery; in Australia, 56.5% had interval debulking surgery. Bevacizumab was included in primary/maintenance therapy for 22.4%, 14.6% and 6.8% of patients in Australia, S.Korea and Taiwan, respectively. Patients receiving bevacizumab were high-risk (reimbursement policy) and achieved similar real-world progression-free survival (PFS) compared with CT only. Overall, the median real-world PFS (months; 95% CI) was similar across Australia (16.0 [14.63–18.08]), S.Korea (17.7 [16.18–19.27]) and Taiwan (19.1 [17.56–22.29]).
Conclusion
This study reveals poor prognosis despite differences in demographics and treatment patterns for patients with EOC across Asia-Pacific suggesting the need for biomarker-driven novel therapies to improve outcomes.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Advanced ovarian cancer: what should be the standard of care?
- Insights into ovarian cancer care: report from the ANZGOG Ovarian Cancer Webinar Series 2020
- The relationship between serum p53 autoantibodies and prognostic relevance of epithelial ovarian cancer
- Correlation between preoperative serum levels of five biomarkers and relationships between these biomarkers and cancer stage in epithelial overian cancer
- A Case of Recurrent Early-stage Epithelial Ovarian Cancer Presenting as Bone Metastasis
